"If you have a very large benefit, they'll be able to accept a little more risk."

— Gil Van Bakkelen, CEO/chairman of Athersys, addressing the question of whether the FDA allows more risk in device treatment than drug treatment of obesity, "Devices hold top billing over pharma solutions for obesity," pp. 1, 7.